

Hospira - Recall of bleomycin injection

 On December 22, 2023, <u>Hospira, a Pfizer company, announced</u> a consumer level recall of one lot of <u>bleomycin for injection</u>, due to a confirmed customer report for the presence of glass particulate within a single vial.

Product Description	NDC#	Lot# (Expiration Date)
Bleomycin for injection, 15 units single-dose ONCO-TAIN [™] glass fliptop vial	61703-332-18	BL12206A (6/30/2024)

- Bleomycin should be considered a palliative treatment useful in the management of neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents.
- Should a patient receive injectable product containing glass particulate matter as a result of this
 issue, the patient may experience adverse events including injection site reaction, localized vein
 inflammation or phlebitis, thrombus, embolus and/or end-organ granuloma or life-threatening
 blood clot events. The risk is reduced by the possibility of detection, as the label contains a
 statement directing the healthcare professional to visually inspect the product for particulate
 matter and discoloration prior to administration.
- To date, Hospira has not received any reports of adverse events related to this recall.
- Anyone with the affected lots on hand should stop distribution and return product.
- Contact Pfizer/Hospira at 1-800-438-1985 or access <u>www.pfizermedinfo.com</u> for questions regarding this recall.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.